Role of a genotype MTBDRplus line probe assay in early detection of multidrug-resistant tuberculosis at a Brazilian reference center

Brazilian Journal of Medical and Biological Research

Volumn 48, Issue 8, 2015, Pages 759-764

  Feliciano, C S ^a   Nascimento, M M P ^a   Anselmo, L M P ^a   Pocente, R H C ^a   Bellissimo Rodrigues, F ^a   Bollela, V R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Molecular diagnostic techniques; Multidrug resistant tuberculosis; Risk factors

Indexed keywords

ISONIAZID; RIFAMPICIN; BACTERIAL DNA; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; BACTERIAL GENE; BRAZIL; DRUG DEPENDENCE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEALTH PRACTITIONER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INHA GENE; KATG GENE; LINE PROBE ASSAY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSTICS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; NONHUMAN; PRISONER; RAPID TEST; RISK FACTOR; RPOB GENE; SMOKING; TREATMENT FAILURE; DRUG EFFECTS; GENETICS; GENOTYPING TECHNIQUE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PROCEDURES; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

BACILLI (CLASS); MYCOBACTERIUM TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; BRAZIL; DNA, BACTERIAL; EARLY DIAGNOSIS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84938683478     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20154458     Document Type: Article

References (24)

1. WHO (World Health Organization). Global tuberculosis report 2013. Geneva: World Health Organization; 2013
2. Brazil Ministry of Health. Boletim epidemiológico 44. O controle da tuberculose no Brasil: Avanc¸os, inovac¸ões e desafios. http://portalsaude.saude.gov.br/images/pdf/2014/maio/29/BE-2014-44--2----Tuberculose.pdf. Accessed January 19, 2014
3. Kritski AL. [Multidrug-resistant tuberculosis emergence: a renewed challenge]. J Bras Pneumol 2010; 36: 157-158, doi:10.1590/S1806-37132010000200001.
4. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, et al. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis 2010; 10: 41, doi:10.1186/1471-2334-10-41.
5. Bastos GM, Cezar MC, Mello FC, Conde MB. Prevalence of primary drug resistance in pulmonary tuberculosis patients with no known risk factors for such. J Bras Pneumol 2012; 38: 733-739, doi:10.1590/S1806-37132012000600008.
6. Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012; 367: 931-936.
7. Nicolau I, Ling D, Tian L, Lienhardt C, Pai M. Research questions and priorities for tuberculosis: a survey of published systematic reviews and meta-analyses. PLoS One 2012; 7: e42479, doi:10.1371/journal.pone.0042479
8. WHO (World Health Organization). Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). Policy statement. Geneva: World Health Organization; 2008, http://www.who.int/tb/features_archive/policy_statement.pdf.
9. Bollela VR, Sato DN, Fonseca BA. McFarland nephelometer as a simple method to estimate the sensitivity of the polymerase chain reaction using Mycobacterium tuberculosis as a research tool. Braz J Med Biol Res 1999; 32: 1073-1076, doi:10.1590/S0100-879X1999000900003.
10. Vijdea R, Stegger M, Sosnovskaja A, Andersen AB, Thomsen VO, Bang D. Multidrug-resistant tuberculosis: rapid detection of resistance to rifampin and high or low levels of isoniazid in clinical specimens and isolates. Eur J Clin Microbiol Infect Dis 2008; 27: 1079-1086, doi:10.1007/s10096-008-0548-9.
11. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90: 111-119D, doi:10.2471/BLT.11.092585.
12. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45: 2635-2640.
13. Yadav RN, Singh BK, Sharma SK, Sharma R, Soneja M, Sreenivas V, et al. Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India. PLoS One 2013; 8: e72036, doi:10.1371/journal.pone.0072036.
14. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Roses S, et al. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2008; 46: 3660-3667.
15. Kipiani M, Mirtskhulava V, Tukvadze N, Magee M, Blumberg HM, Kempker RR. Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59: 1559-1566, doi:10.1093/cid/ciu631.
16. Jacobson KR, Theron D, Kendall EA, Franke MF, Barnard M, van Helden PD, et al. Implementation of genotype MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa. Clin Infect Dis 2013; 56: 503-508, doi:10.1093/cid/cis920.
17. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 2006; 61: 158-163, doi:10.1136/thx.2005.045963.
18. Liang L, Wu Q, Gao L, Hao Y, Liu C, Xie Y, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax 2012; 67: 632-638, doi:10.1136/thoraxjnl-2011-200018.
19. Ricks PM, Mavhunga F, Modi S, Indongo R, Zezai A, Lambert LA, et al. Characteristics of multidrug-resistant tuberculosis in Namibia. BMC Infect Dis 2012; 12: 385, doi:10.1186/1471-2334-12-385.
20. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 2013; 91: 36-45, doi:10.2471/BLT.12.104588.
21. Barroso EC, Mota RMS, Santos RO, Sousa ALO, Barroso JB, Rodrigues JLN. Risk factors for acquired multidrug resistant tuberculosis. J Pneumol 2003; 29: 89-97.
22. Coelho AG, Zamarioli LA, Telles MA, Ferrazoli L, Waldman EA. A study of multidrug-resistant tuberculosis in risk groups in the city of Santos, São Paulo, Brazil. Mem Inst Oswaldo Cruz 2012; 107: 760-766, doi:10.1590/S0074-02762012000600009.
23. Micheletti VC, Moreira JS, Ribeiro MO, Kritski AL, Braga JU. Drug-resistant tuberculosis in subjects included in the Second National Survey on Antituberculosis Drug Resistance in Porto Alegre, Brazil. J Bras Pneumol 2014; 40: 155-163, doi:10.1590/S1806-37132014000200009.
24. Suchindran S, Brouwer ES, Van RA. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One 2009; 4: e5561, doi:10.1371/journal.pone.0005561